Abiopharma

🔍 Torley Helen (Director)

Company: HALOZYME THERAPEUTICS, INC. (HALO)

Report Date: 2026-08-17

Detailed Transactions and Holdings:

• Acquired 20,000 shares of Common Stock at $18.41 per share (Direct)
  Date: 2026-08-17 | Code: M | equity_swap_involved: 0 | shares_owned_after: 787,780.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 900 shares of Common Stock at $98.958 per share (Direct)
  Date: 2026-08-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 786,880.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 500 shares of Common Stock at $100.457 per share (Direct)
  Date: 2026-08-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 786,380.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 2,100 shares of Common Stock at $101.766 per share (Direct)
  Date: 2026-08-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 784,280.00 | transaction_form_type: 4 | Footnotes: F1, F4
• Sold 9,000 shares of Common Stock at $102.553 per share (Direct)
  Date: 2026-08-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 775,280.00 | transaction_form_type: 4 | Footnotes: F1, F5
• Sold 7,500 shares of Common Stock at $103.482 per share (Direct)
  Date: 2026-08-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 767,780.00 | transaction_form_type: 4 | Footnotes: F1, F6
• Acquired 20,000 shares of Common Stock at $18.41 per share (Direct)
  Date: 2026-08-18 | Code: M | equity_swap_involved: 0 | shares_owned_after: 787,780.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 5,703 shares of Common Stock at $103.083 per share (Direct)
  Date: 2026-08-18 | Code: S | equity_swap_involved: 0 | shares_owned_after: 782,077.00 | transaction_form_type: 4 | Footnotes: F1, F7
• Sold 4,897 shares of Common Stock at $104.11 per share (Direct)
  Date: 2026-08-18 | Code: S | equity_swap_involved: 0 | shares_owned_after: 777,180.00 | transaction_form_type: 4 | Footnotes: F1, F8
• Sold 9,400 shares of Common Stock at $104.874 per share (Direct)
  Date: 2026-08-18 | Code: S | equity_swap_involved: 0 | shares_owned_after: 767,780.00 | transaction_form_type: 4 | Footnotes: F1, F9
• Acquired 20,000 shares of Common Stock at $18.41 per share (Direct)
  Date: 2026-08-19 | Code: M | equity_swap_involved: 0 | shares_owned_after: 787,780.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 7,200 shares of Common Stock at $106.358 per share (Direct)
  Date: 2026-08-19 | Code: S | equity_swap_involved: 0 | shares_owned_after: 780,580.00 | transaction_form_type: 4 | Footnotes: F1, F10
• Sold 9,600 shares of Common Stock at $107.224 per share (Direct)
  Date: 2026-08-19 | Code: S | equity_swap_involved: 0 | shares_owned_after: 770,980.00 | transaction_form_type: 4 | Footnotes: F1, F11
• Sold 3,200 shares of Common Stock at $107.765 per share (Direct)
  Date: 2026-08-19 | Code: S | equity_swap_involved: 0 | shares_owned_after: 767,780.00 | transaction_form_type: 4 | Footnotes: F1, F12
• Sold 20,000 shares of Option to Purchase Common Stock at $18.41 per share (Derivative)
  Date: 2026-08-17 | Code: M | Expires: 2028-02-14 | equity_swap_involved: 0 | shares_owned_after: 181,552.00 | transaction_form_type: 4 | Footnotes: F1, F13
• Sold 20,000 shares of Option to Purchase Common Stock at $18.41 per share (Derivative)
  Date: 2026-08-18 | Code: M | Expires: 2028-02-14 | equity_swap_involved: 0 | shares_owned_after: 161,552.00 | transaction_form_type: 4 | Footnotes: F1, F13
• Sold 20,000 shares of Option to Purchase Common Stock at $18.41 per share (Derivative)
  Date: 2026-08-19 | Code: M | Expires: 2028-02-14 | equity_swap_involved: 0 | shares_owned_after: 141,552.00 | transaction_form_type: 4 | Footnotes: F1, F13

Footnotes:

• F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028.
• F2: Represents a weighted average sales price per share. The shares were sold at prices ranging from $98.580 to $99.210. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
• F3: Represents a weighted average sales price per share. The shares were sold at prices ranging from $99.980 to $100.780. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
• F4: Represents a weighted average sales price per share. The shares were sold at prices ranging from $101.140 to $102.120. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
• F5: Represents a weighted average sales price per share. The shares were sold at prices ranging from $102.140 to $103.050. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
• F6: Represents a weighted average sales price per share. The shares were sold at prices ranging from $103.160 to $104.010. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
• F7: Represents a weighted average sales price per share. The shares were sold at prices ranging from $102.550 to $103.540. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
• F8: Represents a weighted average sales price per share. The shares were sold at prices ranging from $103.570 to $104.550. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
• F9: Represents a weighted average sales price per share. The shares were sold at prices ranging from $104.585 to $105.080 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
• F10: Represents a weighted average sales price per share. The shares were sold at prices ranging from $105.69 to $106.680 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
• F11: Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.69 to $107.680 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
• F12: Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.69 to $107.900 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
• F13: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 14, 2018.